BUZZ-Cara drops on scrapping of neurological condition study, strategic options plan

Reuters06-13

** Shares of Cara Therapeutics fall 20.03% to 54 cents premarket

** Co late on Wednesday said it will wind down studying its drug for a type of neurological condition after it did not show a meaningful clinical benefit at any dose compared to placebo

** Adds, will explore strategic alternatives

** Co was studying oral difelikefalin in adult patients with notalgia paresthetica, a neurological condition that causes intense itching, in a mid-to-late stage trial

** Brokerage Canaccord Genuity downgrades to hold from buy, cuts PT to $1 from $10

** Says it is difficult to predict what the results of any upcoming strategic initiatives might be

** Up to last close, stock down ~9% YTD

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2443506718?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-13 18:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2443506718","market":"us","top_or_hot":-1,"title":"BUZZ-Cara drops on scrapping of neurological condition study, strategic options plan","media":"Reuters","content":"<html><body><p>** Shares of Cara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>    fall 20.03% to 54 cents premarket</p><p>   ** Co late on Wednesday said it will wind down studying its drug for a type of neurological condition after it did not show a meaningful clinical benefit at any dose compared to placebo</p><p>   ** Adds, will explore strategic alternatives</p><p>   ** Co was studying oral difelikefalin in adult patients with notalgia paresthetica, a neurological condition that causes intense itching, in a mid-to-late stage trial</p><p>    ** Brokerage Canaccord Genuity downgrades to hold from buy, cuts PT to $1 from $10</p><p>   ** Says it is difficult to predict what the results of any upcoming strategic initiatives might be</p><p>   ** Up to last close, stock down ~9% YTD</p><p> (Reporting by Sriparna Roy in Bengaluru)</p><p>((Sriparna.Roy@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Cara drops on scrapping of neurological condition study, strategic options plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Cara drops on scrapping of neurological condition study, strategic options plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-13 18:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>** Shares of Cara Therapeutics    fall 20.03% to 54 cents premarket   ** Co late on Wednesday said it will wind down studying its drug for a type of neurological condition after it did not show a ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BUZZ","symbol_name":"VanEck Social Sentiment ETF","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2443506718","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2443506718","pubTimestamp":1718276270,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** Shares of Cara Therapeutics    fall 20.03% to 54 cents premarket   ** Co late on Wednesday said it will wind down studying its drug for a type of neurological condition after it did not show a meaningful clinical benefit at any dose compared to placebo   ** Adds, will explore strategic alternatives   ** Co was studying oral difelikefalin in adult patients with notalgia paresthetica, a neurological condition that causes intense itching, in a mid-to-late stage trial    ** Brokerage Canaccord Genuity downgrades to hold from buy, cuts PT to $1 from $10   ** Says it is difficult to predict what the results of any upcoming strategic initiatives might be   ** Up to last close, stock down ~9% YTD ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"BUZZ":"VanEck Social Sentiment ETF","CARA":"Cara Therapeutics, Inc."},"translate_title":"BUZZ-Cara放弃了神经系统疾病研究和战略选择计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BUZZ":1,"CARA":0.9},"content_text":"** Shares of Cara Therapeutics    fall 20.03% to 54 cents premarket   ** Co late on Wednesday said it will wind down studying its drug for a type of neurological condition after it did not show a meaningful clinical benefit at any dose compared to placebo   ** Adds, will explore strategic alternatives   ** Co was studying oral difelikefalin in adult patients with notalgia paresthetica, a neurological condition that causes intense itching, in a mid-to-late stage trial    ** Brokerage Canaccord Genuity downgrades to hold from buy, cuts PT to $1 from $10   ** Says it is difficult to predict what the results of any upcoming strategic initiatives might be   ** Up to last close, stock down ~9% YTD (Reporting by Sriparna Roy in Bengaluru)((Sriparna.Roy@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2443506718"}